×
Click if you have patients on Pushtronex® system and need information on transition to a new device
High LDL-C Injection Treatment | Repatha® (evolocumab)
INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease.. READ MORE

    • For US healthcare professionals

    Patients IconPatients Icon

    IDENTIFY
    Patients at Very High Risk

    ~50% of ASCVD patients are at very high risk for another CV event2,3,*
    United States IconUnited States Icon

    EXPLORE Broad Coverage and Affordability

    Among commercially insured patients, Repatha® is covered for 98% of commercial lives4,†
    Co-Pay Card IconCo-Pay Card Icon

    ACCESS Amgen® SupportPlus

    With the Repatha® Co-Pay Card, eligible commercial patients may pay as little as $15 per month‡

    >3.7

    million patients

    have received Repatha® worldwide5,§

    REVIEW SAFETY DATA
    Have you seen
    Amgen’s new campaign?
    Watch the commercial to learn what Repatha® can do for your patients

    *Based on the proportion of patients with ASCVD at very high risk for a cardiovascular event using IQVIA LAAD claims data and patient data linked between Quest Diagnostics and IQVIA from January 2018 to December 2022 in the United States.2

    †Covered includes Covered, Covered (PA/ST), Preferred, and Preferred (PA/ST) as defined by Managed Markets Insights and Technology (MMIT) data. Number of commercially insured lives provided is obtained from MMIT for commercial health plans in the United States as of August 2024.

    ‡Eligibility criteria and program maximums apply. Please see full Terms and Conditions at Repatha.com/copaytcs.

    §Cumulative post-market exposure estimates from July 2015 through May 2024, on patients that have received at least 1 dose administration of the product. The number of patients receiving at least 1 administration is estimated using worldwide unit sales data, prescription claims data, and applying utilization assumptions to calculate the unique number of patients. Sources include Amgen Finance Electronic Data Warehouse, IQVIA prescription claims, and MarketScan claims data. The estimates assume patient self-administration, based on filled prescriptions.

    IQVIA, IMS Quintiles Virtual Information Access; LAAD, longitudinal access and adjudication data.

    References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Data on file, Amgen; 2023. 3. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418.
    4. Data on file, Amgen; [1]; 2024. 5. Data on file, Amgen; [2]; 2024.

    Important Safety Information

    Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease
    • as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

    Please see full Prescribing Information.

    Important Safety Information

    Back To Top